Literature DB >> 22668874

Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients.

Bogdan Procopet1, Christophe Bureau, Sophie Métivier, Janick Selves, Marie Angèle Robic, Camille Christol, Mircea Grigorescu, Jean-Pierre Vinel, Jean-Marie Péron.   

Abstract

BACKGROUND: Transjugular liver biopsy (TJLB) is usually performed when a percutaneous liver biopsy (PLB) is contraindicated. TJLB is an invasive procedure and the patient's tolerance may be variable. AIM: To compare patient tolerance and quality of the biopsy sample between PLB and TJLB. PATIENTS AND METHODS: A total of 143 patients underwent a liver biopsy; of these, 75 underwent TJLB and 68 underwent PLB. To evaluate patient tolerance, we used a visual analog scale that scored the intensity of the symptoms. The length of the biopsy sample and the total number of portal tracts per biopsy were also determined for assessment of biopsy quality.
RESULTS: The biopsy sample length was similar in both groups (18.88 ± 8.83 mm on PLB vs. 18.26 ± 10.30 mm on TJLB). No differences were found in the number of portal tracts between the two groups (10.43 ± 8.25 on TJLB vs. 12 ± 10.09 on PLB). Fewer complications were observed in the TJLB group compared with the PLB group (P=0.002).Further, higher degree of pain was reported by patients who underwent PLB compared with patients who underwent TJLB (3.18 ± 3.17 vs. 1.19 ± 2.07); as such, there was a greater need for analgesics on PLB.
CONCLUSION: TJLB and PLB techniques provide similar quality of tissue samples; however, TJLB is less painful and therefore better tolerated by patients.

Entities:  

Mesh:

Year:  2012        PMID: 22668874     DOI: 10.1097/MEG.0b013e328355e2ba

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Serum ferritin as a biomarker for NAFLD: ready for prime time?

Authors:  Raj A Shah; Kris V Kowdley
Journal:  Hepatol Int       Date:  2019-02-09       Impact factor: 6.047

2.  Liver: Transjugular liver biopsy yields high-quality samples.

Authors:  Evangelos Cholongitas; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-31       Impact factor: 46.802

Review 3.  Transjugular Liver Biopsy: A Case of a Phrenic Vein Mimic of the Right Hepatic Vein.

Authors:  Mithil B Pandhi; Ali Kord; Matthew M Niemeyer
Journal:  Semin Intervent Radiol       Date:  2022-02-18       Impact factor: 1.513

Review 4.  The role of interventional radiology in the management of hepatocellular carcinoma.

Authors:  N Molla; N AlMenieir; E Simoneau; M Aljiffry; D Valenti; P Metrakos; L M Boucher; M Hassanain
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

Review 5.  Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia.

Authors:  Domenico Alvaro; Nicola Caporaso; Edoardo Giovanni Giannini; Angelo Iacobellis; Mariacristina Morelli; Pierluigi Toniutto; Francesco Violi
Journal:  Eur J Clin Invest       Date:  2021-02-26       Impact factor: 4.686

6.  Non-invasive evaluation of liver stiffness after splenectomy in rabbits with CCl4-induced liver fibrosis.

Authors:  Ming-Jun Wang; Wen-Wu Ling; Hong Wang; Ling-Wei Meng; He Cai; Bing Peng
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

7.  Safety and adequacy of endoscopic ultrasound-guided random liver biopsy in comparison with transjugular and percutaneous approaches.

Authors:  Neil Bhogal; Bernadette Lamb; Benjamin Arbeiter; Sarah Malik; Harlan Sayles; Audrey J Lazenby; Saurabh Chandan; Amaninder Dhaliwal; Shailender Singh; Ishfaq Bhat
Journal:  Endosc Int Open       Date:  2020-11-17

8.  Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Helena B Thomaides-Brears; Naim Alkhouri; Daniela Allende; Mukesh Harisinghani; Mazen Noureddin; Nancy S Reau; Marika French; Carlos Pantoja; Sofia Mouchti; Donna R H Cryer
Journal:  Dig Dis Sci       Date:  2021-06-15       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.